Loading…
Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration
Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potential role and mechanisms of bone marrow-derived MSCs (BM-MSCs) in colitis-associated colon can...
Saved in:
Published in: | Journal of translational medicine 2023-03, Vol.21 (1), p.227-227, Article 227 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33 |
---|---|
cites | cdi_FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33 |
container_end_page | 227 |
container_issue | 1 |
container_start_page | 227 |
container_title | Journal of translational medicine |
container_volume | 21 |
creator | Hu, Weiqian Wang, Weijun Jiang, Xin Wang, Zeyu Lin, Rong |
description | Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potential role and mechanisms of bone marrow-derived MSCs (BM-MSCs) in colitis-associated colon cancer (CAC) were investigated.
The CAC mouse model was established with azoxymethane (AOM) and dextran sulfate sodium (DSS). The mice were administered an intraperitoneal injection of MSCs once weekly for different periods. The progression of CAC and the cytokine expression in tissues was assessed. Immunofluorescence staining was used to detect MSCs localization. Levels of immune cells in the spleen and lamina propria of the colon were detected using flow cytometry. A co-culture of MSCs and naïve T cells was performed to determine the effect of MSCs on naïve T cell differentiation.
Early administration of MSCs inhibited the occurrence of CAC, while late administration promoted the progression of CAC. The inhibitory effect of early injection in mice was characterized by the expression of inflammatory cytokines in colon tissue was decreased, and induction of T regulatory cells (Tregs) infiltration via TGF-β. The promotive effect of late injection was characterized by a shift of T helper (Th) 1/Th2 immune balance toward a Th2 phenotype through IL-4 secretion. IL-12 can reverse this shift to Th2 accumulation in mice.
MSCs can curb the progression of colon cancer by inducing Treg accumulation via TGF-β at the early stage of inflammatory transformation but promote the progression of colon cancer by inducing a shift in Th1/Th2 immune balance to Th2 through IL-4 secretion at the late stage. And the immune balance of Th1/Th2 influenced by MSCs could be reversed by IL-12. |
doi_str_mv | 10.1186/s12967-023-04028-3 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_28a8292fc38e48249070b923cb64326d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743448726</galeid><doaj_id>oai_doaj_org_article_28a8292fc38e48249070b923cb64326d</doaj_id><sourcerecordid>A743448726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33</originalsourceid><addsrcrecordid>eNptUk1v1DAUjBCIlsIf4IAsceGS4q_Y8QlVFR-VirjA2XLs56xXib3Y2Ur99zjdUu0i5IPHz_PGfqNpmrcEXxLSi4-FUCVkiylrMce0b9mz5pxwqdqul-L5ET5rXpWyxZjyjquXzRkTSvaE4vNm_x0KRLu5n82EygIzsjBNBVkT0S7DHcQFpVxhmtMCaNnAiscMpYQUUfLIpqmCyreQ0WAKOFTPlRgyWsIc4riyjKsolCWbpfa9bl54MxV487hfNL--fP55_a29_fH15vrqtrWd4EvrBqcG8MIb5R0zHRWmw0JxSqwngoNQDoBhqC4QrvwARkrRD4wPlBNwjF00Nwddl8xW73KYTb7XyQT9UEh51CYvwU6gaW96qqi3rAfeU66wxIOizA6CMypc1fp00Nrthxmcrc5kM52Int7EsNFjutMEY94Jsv7mw6NCTr_3UBY9h7LabSKkfdFUKtphipms1Pf_ULdpn2P1qn4UMywlk0es0dQJQvSpPmxXUX0lOeO8l1RU1uV_WHU5mINNEXyo9ZMGemiwOZWSwT8NSbBek6cPydM1efoheXod7t2xPU8tf6PG_gAGPdQk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803077377</pqid></control><display><type>article</type><title>Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content (ProQuest)</source><creator>Hu, Weiqian ; Wang, Weijun ; Jiang, Xin ; Wang, Zeyu ; Lin, Rong</creator><creatorcontrib>Hu, Weiqian ; Wang, Weijun ; Jiang, Xin ; Wang, Zeyu ; Lin, Rong</creatorcontrib><description>Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potential role and mechanisms of bone marrow-derived MSCs (BM-MSCs) in colitis-associated colon cancer (CAC) were investigated.
The CAC mouse model was established with azoxymethane (AOM) and dextran sulfate sodium (DSS). The mice were administered an intraperitoneal injection of MSCs once weekly for different periods. The progression of CAC and the cytokine expression in tissues was assessed. Immunofluorescence staining was used to detect MSCs localization. Levels of immune cells in the spleen and lamina propria of the colon were detected using flow cytometry. A co-culture of MSCs and naïve T cells was performed to determine the effect of MSCs on naïve T cell differentiation.
Early administration of MSCs inhibited the occurrence of CAC, while late administration promoted the progression of CAC. The inhibitory effect of early injection in mice was characterized by the expression of inflammatory cytokines in colon tissue was decreased, and induction of T regulatory cells (Tregs) infiltration via TGF-β. The promotive effect of late injection was characterized by a shift of T helper (Th) 1/Th2 immune balance toward a Th2 phenotype through IL-4 secretion. IL-12 can reverse this shift to Th2 accumulation in mice.
MSCs can curb the progression of colon cancer by inducing Treg accumulation via TGF-β at the early stage of inflammatory transformation but promote the progression of colon cancer by inducing a shift in Th1/Th2 immune balance to Th2 through IL-4 secretion at the late stage. And the immune balance of Th1/Th2 influenced by MSCs could be reversed by IL-12.</description><identifier>ISSN: 1479-5876</identifier><identifier>EISSN: 1479-5876</identifier><identifier>DOI: 10.1186/s12967-023-04028-3</identifier><identifier>PMID: 36978120</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Angiogenesis ; Animal models ; Animals ; Antigens ; Azoxymethane ; Bone marrow ; Care and treatment ; CD4+T cells ; Cell culture ; Cell differentiation ; Colitis ; Colitis-associated colon cancer ; Colon - pathology ; Colon cancer ; Colonic Neoplasms - pathology ; Colorectal cancer ; Cytokines ; Cytokines - metabolism ; Development and progression ; Dextran ; Dextran sulfate ; Dextran Sulfate - adverse effects ; Disease ; Disease Models, Animal ; Flow cytometry ; Health aspects ; Immunofluorescence ; Immunomodulatory ; Immunoregulation ; Inflammation ; Inflammatory bowel disease ; Injection ; Interleukin 12 ; Interleukin 4 ; Interleukin-12 - metabolism ; Interleukin-4 - metabolism ; Lamina propria ; Localization ; Lymphocytes ; Lymphocytes T ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stem Cells ; Metastases ; Mice ; Mice, Inbred C57BL ; Phenotypes ; Risk factors ; Stem cells ; T-Lymphocytes, Regulatory ; Testing ; Transforming Growth Factor beta - metabolism ; Transforming growth factor-b ; Tumor necrosis factor-TNF ; Tumors</subject><ispartof>Journal of translational medicine, 2023-03, Vol.21 (1), p.227-227, Article 227</ispartof><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33</citedby><cites>FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045613/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2803077377?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,25740,27911,27912,36999,37000,44577,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36978120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Weiqian</creatorcontrib><creatorcontrib>Wang, Weijun</creatorcontrib><creatorcontrib>Jiang, Xin</creatorcontrib><creatorcontrib>Wang, Zeyu</creatorcontrib><creatorcontrib>Lin, Rong</creatorcontrib><title>Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration</title><title>Journal of translational medicine</title><addtitle>J Transl Med</addtitle><description>Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potential role and mechanisms of bone marrow-derived MSCs (BM-MSCs) in colitis-associated colon cancer (CAC) were investigated.
The CAC mouse model was established with azoxymethane (AOM) and dextran sulfate sodium (DSS). The mice were administered an intraperitoneal injection of MSCs once weekly for different periods. The progression of CAC and the cytokine expression in tissues was assessed. Immunofluorescence staining was used to detect MSCs localization. Levels of immune cells in the spleen and lamina propria of the colon were detected using flow cytometry. A co-culture of MSCs and naïve T cells was performed to determine the effect of MSCs on naïve T cell differentiation.
Early administration of MSCs inhibited the occurrence of CAC, while late administration promoted the progression of CAC. The inhibitory effect of early injection in mice was characterized by the expression of inflammatory cytokines in colon tissue was decreased, and induction of T regulatory cells (Tregs) infiltration via TGF-β. The promotive effect of late injection was characterized by a shift of T helper (Th) 1/Th2 immune balance toward a Th2 phenotype through IL-4 secretion. IL-12 can reverse this shift to Th2 accumulation in mice.
MSCs can curb the progression of colon cancer by inducing Treg accumulation via TGF-β at the early stage of inflammatory transformation but promote the progression of colon cancer by inducing a shift in Th1/Th2 immune balance to Th2 through IL-4 secretion at the late stage. And the immune balance of Th1/Th2 influenced by MSCs could be reversed by IL-12.</description><subject>Angiogenesis</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antigens</subject><subject>Azoxymethane</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>CD4+T cells</subject><subject>Cell culture</subject><subject>Cell differentiation</subject><subject>Colitis</subject><subject>Colitis-associated colon cancer</subject><subject>Colon - pathology</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Development and progression</subject><subject>Dextran</subject><subject>Dextran sulfate</subject><subject>Dextran Sulfate - adverse effects</subject><subject>Disease</subject><subject>Disease Models, Animal</subject><subject>Flow cytometry</subject><subject>Health aspects</subject><subject>Immunofluorescence</subject><subject>Immunomodulatory</subject><subject>Immunoregulation</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Injection</subject><subject>Interleukin 12</subject><subject>Interleukin 4</subject><subject>Interleukin-12 - metabolism</subject><subject>Interleukin-4 - metabolism</subject><subject>Lamina propria</subject><subject>Localization</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Mesenchymal Stem Cell Transplantation</subject><subject>Mesenchymal Stem Cells</subject><subject>Metastases</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Phenotypes</subject><subject>Risk factors</subject><subject>Stem cells</subject><subject>T-Lymphocytes, Regulatory</subject><subject>Testing</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>Transforming growth factor-b</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><issn>1479-5876</issn><issn>1479-5876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAUjBCIlsIf4IAsceGS4q_Y8QlVFR-VirjA2XLs56xXib3Y2Ur99zjdUu0i5IPHz_PGfqNpmrcEXxLSi4-FUCVkiylrMce0b9mz5pxwqdqul-L5ET5rXpWyxZjyjquXzRkTSvaE4vNm_x0KRLu5n82EygIzsjBNBVkT0S7DHcQFpVxhmtMCaNnAiscMpYQUUfLIpqmCyreQ0WAKOFTPlRgyWsIc4riyjKsolCWbpfa9bl54MxV487hfNL--fP55_a29_fH15vrqtrWd4EvrBqcG8MIb5R0zHRWmw0JxSqwngoNQDoBhqC4QrvwARkrRD4wPlBNwjF00Nwddl8xW73KYTb7XyQT9UEh51CYvwU6gaW96qqi3rAfeU66wxIOizA6CMypc1fp00Nrthxmcrc5kM52Int7EsNFjutMEY94Jsv7mw6NCTr_3UBY9h7LabSKkfdFUKtphipms1Pf_ULdpn2P1qn4UMywlk0es0dQJQvSpPmxXUX0lOeO8l1RU1uV_WHU5mINNEXyo9ZMGemiwOZWSwT8NSbBek6cPydM1efoheXod7t2xPU8tf6PG_gAGPdQk</recordid><startdate>20230328</startdate><enddate>20230328</enddate><creator>Hu, Weiqian</creator><creator>Wang, Weijun</creator><creator>Jiang, Xin</creator><creator>Wang, Zeyu</creator><creator>Lin, Rong</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230328</creationdate><title>Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration</title><author>Hu, Weiqian ; Wang, Weijun ; Jiang, Xin ; Wang, Zeyu ; Lin, Rong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antigens</topic><topic>Azoxymethane</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>CD4+T cells</topic><topic>Cell culture</topic><topic>Cell differentiation</topic><topic>Colitis</topic><topic>Colitis-associated colon cancer</topic><topic>Colon - pathology</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Development and progression</topic><topic>Dextran</topic><topic>Dextran sulfate</topic><topic>Dextran Sulfate - adverse effects</topic><topic>Disease</topic><topic>Disease Models, Animal</topic><topic>Flow cytometry</topic><topic>Health aspects</topic><topic>Immunofluorescence</topic><topic>Immunomodulatory</topic><topic>Immunoregulation</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Injection</topic><topic>Interleukin 12</topic><topic>Interleukin 4</topic><topic>Interleukin-12 - metabolism</topic><topic>Interleukin-4 - metabolism</topic><topic>Lamina propria</topic><topic>Localization</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Mesenchymal Stem Cell Transplantation</topic><topic>Mesenchymal Stem Cells</topic><topic>Metastases</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Phenotypes</topic><topic>Risk factors</topic><topic>Stem cells</topic><topic>T-Lymphocytes, Regulatory</topic><topic>Testing</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>Transforming growth factor-b</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Weiqian</creatorcontrib><creatorcontrib>Wang, Weijun</creatorcontrib><creatorcontrib>Jiang, Xin</creatorcontrib><creatorcontrib>Wang, Zeyu</creatorcontrib><creatorcontrib>Lin, Rong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals (Open Access)</collection><jtitle>Journal of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Weiqian</au><au>Wang, Weijun</au><au>Jiang, Xin</au><au>Wang, Zeyu</au><au>Lin, Rong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration</atitle><jtitle>Journal of translational medicine</jtitle><addtitle>J Transl Med</addtitle><date>2023-03-28</date><risdate>2023</risdate><volume>21</volume><issue>1</issue><spage>227</spage><epage>227</epage><pages>227-227</pages><artnum>227</artnum><issn>1479-5876</issn><eissn>1479-5876</eissn><abstract>Mesenchymal stem cell (MSC) therapy has been shown to have some therapeutic effects in rodent models and patients with IBD; however, its role in colon tumor models is controversial. In this study, the potential role and mechanisms of bone marrow-derived MSCs (BM-MSCs) in colitis-associated colon cancer (CAC) were investigated.
The CAC mouse model was established with azoxymethane (AOM) and dextran sulfate sodium (DSS). The mice were administered an intraperitoneal injection of MSCs once weekly for different periods. The progression of CAC and the cytokine expression in tissues was assessed. Immunofluorescence staining was used to detect MSCs localization. Levels of immune cells in the spleen and lamina propria of the colon were detected using flow cytometry. A co-culture of MSCs and naïve T cells was performed to determine the effect of MSCs on naïve T cell differentiation.
Early administration of MSCs inhibited the occurrence of CAC, while late administration promoted the progression of CAC. The inhibitory effect of early injection in mice was characterized by the expression of inflammatory cytokines in colon tissue was decreased, and induction of T regulatory cells (Tregs) infiltration via TGF-β. The promotive effect of late injection was characterized by a shift of T helper (Th) 1/Th2 immune balance toward a Th2 phenotype through IL-4 secretion. IL-12 can reverse this shift to Th2 accumulation in mice.
MSCs can curb the progression of colon cancer by inducing Treg accumulation via TGF-β at the early stage of inflammatory transformation but promote the progression of colon cancer by inducing a shift in Th1/Th2 immune balance to Th2 through IL-4 secretion at the late stage. And the immune balance of Th1/Th2 influenced by MSCs could be reversed by IL-12.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>36978120</pmid><doi>10.1186/s12967-023-04028-3</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1479-5876 |
ispartof | Journal of translational medicine, 2023-03, Vol.21 (1), p.227-227, Article 227 |
issn | 1479-5876 1479-5876 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_28a8292fc38e48249070b923cb64326d |
source | PubMed Central (Open Access); Publicly Available Content (ProQuest) |
subjects | Angiogenesis Animal models Animals Antigens Azoxymethane Bone marrow Care and treatment CD4+T cells Cell culture Cell differentiation Colitis Colitis-associated colon cancer Colon - pathology Colon cancer Colonic Neoplasms - pathology Colorectal cancer Cytokines Cytokines - metabolism Development and progression Dextran Dextran sulfate Dextran Sulfate - adverse effects Disease Disease Models, Animal Flow cytometry Health aspects Immunofluorescence Immunomodulatory Immunoregulation Inflammation Inflammatory bowel disease Injection Interleukin 12 Interleukin 4 Interleukin-12 - metabolism Interleukin-4 - metabolism Lamina propria Localization Lymphocytes Lymphocytes T Mesenchymal Stem Cell Transplantation Mesenchymal Stem Cells Metastases Mice Mice, Inbred C57BL Phenotypes Risk factors Stem cells T-Lymphocytes, Regulatory Testing Transforming Growth Factor beta - metabolism Transforming growth factor-b Tumor necrosis factor-TNF Tumors |
title | Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T04%3A39%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mesenchymal%20stem%20cells%20can%20prevent%20or%20promote%20the%20progression%20of%20colon%20cancer%20based%20on%20their%20timing%20of%20administration&rft.jtitle=Journal%20of%20translational%20medicine&rft.au=Hu,%20Weiqian&rft.date=2023-03-28&rft.volume=21&rft.issue=1&rft.spage=227&rft.epage=227&rft.pages=227-227&rft.artnum=227&rft.issn=1479-5876&rft.eissn=1479-5876&rft_id=info:doi/10.1186/s12967-023-04028-3&rft_dat=%3Cgale_doaj_%3EA743448726%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c564t-dbd9bef6fa9fd3a526a5069421cf164e69dee30e967149fbea7768b34b241ed33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2803077377&rft_id=info:pmid/36978120&rft_galeid=A743448726&rfr_iscdi=true |